On March 17, 2026, NPR reported that Title X — the 56-year-old federal program providing free birth control, STI testing, and cancer screenings to low-income patients — faces an imminent funding cliff on March 31. For the first time in 27 years, the application guidance for grant renewals was never released on its December 31, 2025 deadline. When applications finally opened on March 14, grantees were given just one week to submit comprehensive materials — a process that normally takes three to four months.

Why It Matters

Title X is the backbone of reproductive and sexual health access for millions of low-income Americans. A funding disruption would ripple directly through STI testing availability, contraception access, and cancer screening capacity — all core services that intersect with the sexual wellness industry's mission of accessible sexual health. For femtech and sexual health startups that partner with or complement public health infrastructure, the stability of Title X is a baseline assumption. Its potential collapse creates both a crisis and, perversely, a market opportunity for private-sector alternatives.

Clare Coleman, president of the National Family Planning and Reproductive Health Association, called the timeline "laughable," noting that just 10 HHS staffers have seven business days to review dozens of applications covering thousands of clinics nationwide. A total of 128 Democratic members of Congress, organized through the House Democratic Women's Caucus and Reproductive Freedom Caucus, signed a letter urging Health Secretary Robert F. Kennedy Jr. to grant a one-year full funding extension to all current Title X grantees.

The funding crisis caps a turbulent period for the program. The Trump administration had withheld 22 Title X grants for most of 2025 before a lawsuit forced their release, and the entire Title X administration staff was fired during the October 2025 government shutdown. Even brief funding gaps could force health centers to reduce hours, lay off staff, or eliminate services entirely — directly impacting communities that depend on Title X for birth control access, STI testing and treatment, and cancer screenings.

Sources

Update — 2026-03-28

Initial entry — story first created.

Update — 2026-03-31

Today is the funding cliff. As of March 31, 2026, Title X grants expire with no confirmed extension or continuation awards announced publicly. The pressure campaign intensified in the final weeks: Senators Angus King (I-ME), Mazie Hirono (D-HI), and Patty Murray (D-WA) led 38 Senate colleagues in a letter to HHS Secretary Robert F. Kennedy Jr. demanding immediate release of funding. Senator Mark Warner (D-VA) issued a separate demand letter. In total, over 160 members of Congress across both chambers have called for action.

The application process that opened on March 14 — giving grantees just one week instead of the standard three to four months — has been described as unworkable. HHS's 10-person Title X team had seven business days to review dozens of applications covering thousands of clinics nationwide. Without continuation awards, over 2 million patients face potential loss of access to contraception, STI testing and treatment, and cancer screenings. The bipartisan budget signed in February kept Title X funding steady, but President Trump's proposed 2026 budget would defund the program entirely. Any gap in funding — even temporary — could force health centers to reduce hours, lay off staff, or eliminate services entirely.

New Sources

Update — 2026-04-03

The cliff was averted — at least for now. The Trump administration extended Title X family planning grants on March 31, 2026, including to Planned Parenthood, arguing that the previous Biden administration had locked in the funding commitments. The extension covers the fifth year of the grant cycle, with funding starting April 1.

The decision drew immediate condemnation from pro-life leaders who had expected the administration to let the grants lapse. But for the 2.8 million patients who rely on Title X-funded clinics for contraception, STI testing, and cancer screenings, the extension means services continue uninterrupted — for now. President Trump's proposed 2026 budget would still eliminate Title X entirely, meaning the program faces another existential threat when the current grants expire. The chaotic one-week application process and the 27-year precedent break in guidance timing suggest the administration remains hostile to the program even as it extends funding under legal pressure.

New Sources

Update — 2026-04-20

The two-week reprieve has turned into a full policy pivot. Between April 8 and April 14, 2026, HHS published a fiscal-year 2027 Title X funding notice that materially reshapes eligibility and scoring criteria: the new notice gives preference to organizations that emphasize fertility-awareness-based methods and "natural family planning" over hormonal contraception, and penalizes applicants whose service mix leans heavily on LARCs, oral contraceptives, and injectable methods. The FY2027 notice effectively converts Title X from a comprehensive family-planning program into a federally preferenced channel for fertility-awareness organizations.

Reproductive health advocates characterized the pivot as a functional defunding of mainstream Title X clinics by policy rather than by budget. Roll Call reported the FY2027 design is under active congressional scrutiny, with several Democratic members pledging oversight hearings. The timing is especially pointed given the CDC's April 12-18 STI Awareness Week messaging, which highlighted a 145% rise in women's syphilis cases from 2020 to 2024 — the exact screening activity many Title X clinics have historically performed at scale. The new FY2027 framework creates an unexpected tailwind for period-tracking and fertility-awareness app companies (Natural Cycles, Flo, Clue) that could plausibly qualify as preferred providers under the redesigned criteria, while compressing the business model of mainstream reproductive-health clinics.

New Sources

Update — 2026-04-29

The pivot is now formally codified. On April 28, 2026, Salon reported that HHS released a 70-page Title X grant guidance document for clinics reapplying for January 2027 funding — making minimal mention of contraception and explicitly redirecting program priorities toward "natural family planning methods" and "restorative reproductive medicine" (RRM). The document instructs clinics to "strengthen family formation and assist clients in achieving healthy pregnancies" rather than prevent them, and directs grantees to emphasize "body literacy" education on menstrual cycles and fertility awareness over evidence-based contraception.

The new framework was issued the same week the CDC reported U.S. fertility rates at an all-time low — context that HHS uses to justify the pivot, and that critics argue is being weaponized to force ideological program design. Danielle Melfi of RESOLVE warned that "RRM risks steering people away from evidence-based treatments they may need to build their families, like IVF." The American College of Obstetricians and Gynecologists publicly rebuked RRM, saying it "falsely claims endometriosis is the dominant infertility cause" and overlooks established treatments. The April 28 guidance crystallizes what the April 8-14 FY2027 notice signaled: Title X has been converted, by administrative rule rather than statute, from a comprehensive family-planning program into a federally preferenced funnel for fertility-awareness organizations and pregnancy-centered care models.

New Sources